3-(3,4-dihydronaphthalen-1-yl)propanoic acid | 309254-70-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 3-(3,4-dihydronaphthalen-1-yl)propanoic acid
• CAS: 309254-70-4
• 化学式: C₁₃H₁₄O₂
• 分子量: 202.253
• InChiKey: QRBJRLUQYQBGNM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(3,4-dihydronaphthalen-1-yl)propanoic acid 在 palladium on activated charcoal PPA 、 氢气 作用下， 以 乙醇 为溶剂， 20.0~120.0 ℃ 、344.74 kPa 条件下， 反应 0.5h， 生成 (RS)-2,3,3a,4,5,6-hexahydro-phenalen-1-one
  参考文献：
  名称：

  Synthesis and theoretical study of 2-amino-2,3,3a,4,5,6-hexahydro-1H-phenalene and its biological evaluation on central dopaminergic system

  摘要：

  Compound 2 considered as a rigid non-hydroxylated 2-amino tetralin was synthesized and biologically evaluated. Central administration of compound 2 (50 mug or 100 mug/10 mul) induced a reduction in urinary sodium and potassium excretion at 3 and 6 h of urine collection. We speculate that compound 2 may be acting as a dopamine receptor antagonist. (C) 2000 Elsevier Science S.A. All rights reserved.

  DOI：

  10.1016/s0014-827x(00)00081-1
• 作为产物：
  描述：

  alpha-环丙基苯乙烯 在 copper diacetate 、 silver carbonate 、 sodium hydroxide 作用下， 反应 48.0h， 生成 3-(3,4-dihydronaphthalen-1-yl)propanoic acid
  参考文献：
  名称：

  铜促进烷基腈中具有 α-C-H 键的乙烯基环丙烷氰基烷基化/扩环生成 3,4-二氢萘

  摘要：

  建立了铜促进的烷基腈中具有 α-C(sp 3 )-H 键的乙烯基环丙烷的氧化氰甲基化/扩环，用于生成 1-氰乙基化 3,4-二氢萘。这种氰甲基化/扩环涉及自由基途径，并通过氰甲基自由基形成、自由基加成和扩环进行。这种扩环策略为构建含腈的 3,4-二氢萘提供了一条高度原子经济的路线，可以在简单的条件下将其转化为其他有用的产品。

  DOI：

  10.1039/d0ob01864c

文献信息

• Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
  申请人：Den Hartog A.J. Jacobus

  公开号：US20050070528A1

  公开（公告）日：2005-03-31

  The invention relates to a group of novel benzimidazolone and quinazolinone derivatives which are agonists on human ORL1 (nociceptin) receptors. The invention also relates to the preparation of these compounds, to pharmaceutical compositions containing a pharmacologically active amount of at least one of these imidazolone and quinazolinone derivatives as an active ingredient, as well as to the use of these pharmaceutical compositions for the treatment of disorders in which ORL1 receptors are involved. The invention relates to compounds of the general formula (1): wherein the symbols have the meanings as given in the description.

  该发明涉及一组新型苯并咪唑酮和喹唑酮衍生物，这些衍生物是人类ORL1（nociceptin）受体的激动剂。该发明还涉及制备这些化合物，含有至少一种这些咪唑酮和喹唑酮衍生物的药理活性量作为活性成分的药物组合物，以及利用这些药物组合物治疗涉及ORL1受体的疾病。该发明涉及一般公式（1）的化合物：其中符号的含义如描述中所述。
• Synthesis of CHF₂-Containing Heterocycles through Oxy-difluoromethylation Using Low-Cost 3D Printed PhotoFlow Reactors
  作者：Jinlei Zhang、Elias Selmi-Higashi、Shen Zhang、Alexandre Jean、Stephen T. Hilton、Xacobe C. Cambeiro、Stellios Arseniyadis

  DOI：10.1021/acs.orglett.3c03997

  日期：2024.4.12

  We report here a highly straightforward access to a variety of CHF2-containing heterocycles, including lactones, tetrahydrofurans, tetrahydropyrans, benzolactones, phthalanes, and pyrrolidines, through a visible light-mediated intramolecular oxy-difluoromethylation under continuous flow. The method, which relies on the use of readily available starting materials, low-cost 3D printed photoflow reactors

  我们在这里报道了通过连续流动下可见光介导的分子内氧二氟甲基化，高度直接地获得各种含CHF 2的杂环，包括内酯、四氢呋喃、四氢吡喃、苯内酯、酞烷和吡咯烷。该方法依赖于使用容易获得的起始材料、低成本的3D打印光流反应器以及此处用作CHF2自由基前体的二氟甲基三苯基溴化鏻，该方法实用且可扩展，并以中等至优异的产率和优异的性能提供所需的产品。区域选择性和立体选择性。
• Johnson; Johnson; Petersen, Journal of the American Chemical Society, 1945, vol. 67, p. 1360,1364
  作者：Johnson、Johnson、Petersen

  DOI：——

  日期：——
• Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one, a potent and selective orphanin FQ (OFQ) receptor agonist with anxiolytic-like properties
  作者：J Wichmann

  DOI：10.1016/s0223-5234(00)00171-9

  日期：2000.9

  The development of 8-(2,3,3a,4,5,6-hexahydro-1H-phenalenl-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones 3 starting from (RS)-s-acenaphten-1-yl-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 1 is reported. The synthesis and the binding affinities at human OFQ and opioid (mu, kappa, delta) receptors of the stereoisomers 3a-f are described. In vitro the most selective compound, (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1 H-phenalenl-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one 3c, was found to act as a full agonist at the OFQ receptor in the GTP gamma(35)S binding test. It turned out to be selective versus a variety of other neurotransmitter systems. When tested in vivo following intraperitoneal injection, compound 3c was found to decrease neophobia in a novel environment and to exhibit dose-dependent anxiolytic-like effects in the elevated plus-maze procedure, thus confirming the effects observed following intracerebroventricular infusion of the OFQ peptide in rat. (C) 2000 Editions scientifiques et medicales Elsevier SAS.
• Julia,M.; Le Goffic,F., Bulletin de la Societe Chimique de France, 1964, p. 1129 - 1133
  作者：Julia,M.、Le Goffic,F.

  DOI：——

  日期：——